Comparison of Animal Models for the Study of Nonalcoholic Fatty Liver Disease

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

“…The progression of NAFLD can result in the development of steatohepatitis, cirrhosis, and liver cancer, posing a significant threat to human health. Numerous animal models of NAFLD have been reported both domestically and internationally in order to study the pathogenesis and efficacy of drug treatments for NAFLD . Among these models, the HFD-induced fatty liver model exhibits pathological characteristics similar to humans, displaying a high success rate, low mortality rate, and a simple and replicable methodology.…”

“…Numerous animal models of NAFLD have been reported both domestically and internationally in order to study the pathogenesis and efficacy of drug treatments for NAFLD. 50 Among these models, the HFD-induced fatty liver model exhibits pathological characteristics similar to humans, displaying a high success rate, low mortality rate, and a simple and replicable methodology. To investigate the impact of various samples on NAFLD, we used an HFD-induced fatty liver model following the experimental cycle depicted in Figure 4A.…”

Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

“…The pathogenesis of NASH is complex and has not been completely understood. However, given the evidence of the pathophysiology of NAFLD and NASH with different dietary animal models [ 8 ], the development of NASH consists of two steps. The first is a fat-accumulating step in the liver that causes insulin resistance, and the second is the process causing liver damage with cellular and molecular changes that involve fatty acid oxidation, oxidative stress, and inflammation in the liver due to various factors [ 6 , 7 ].…”